South San Francisco, United States
Mission Bio, founded in 2014, is a key player in the Biotechnology and Health Care industries, with a focus also on Clean Energy. Headquartered in the United States, the company has carved a niche with its Tapestri® Platform, the only technology that delivers single-cell targeted DNA sequencing at single-base resolution.
The firm originated from Adam Abate's lab at the University of California, San Francisco (UCSF), underscoring its foundation in cutting-edge research and innovation in droplet microfluidics. Mission Bio stands out for its commitment to aiding researchers and clinicians in the advancement of precision medicine through unparalleled precision engineering and bioinformatics.
In its latest funding round, Mission Bio attracted a Growth Equity VC investment on 01 August 2025, with backing from Ally Bridge Group. This investment underscores investor confidence in their innovative technology and future growth potential.
